Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Recap: Sterling Infrastructure Q2 Earnings

Sterling Infrastructure (NASDAQ:STRL) reported its Q2 earnings results on Monday, August 1, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
byBenzinga Insights
August 1, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Sterling Infrastructure (NASDAQ:STRL) reported its Q2 earnings results on Monday, August 1, 2022 at 04:05 PM.

Here’s what investors need to know about the announcement.

Earnings

Sterling Infrastructure beat estimated earnings by 16.22%, reporting an EPS of $0.86 versus an estimate of $0.74.

Revenue was up $108.90 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.22 which was followed by a 0.51% increase in the share price the next day.

Here’s a look at Sterling Infrastructure’s past performance:

 

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate 0.42 0.37 0.60 0.52
EPS Actual 0.64 0.47 0.72 0.69
Revenue Estimate 373.90M 337.60M 402.70M 397.15M
Revenue Actual 410.32M 401.33M 463.45M 401.67M

To track all earnings releases for Sterling Infrastructure visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Hemp-Focused Wellness Co. Moves Closer To Profitability, Reports Flat 2023 Revenue, Increase In Gross Profit

By Jelena Martinovic
March 28, 12:04 PM
Hemp-focused consumer wellness company CV Sciences, Inc. (OTCQB: CVSI) announced on Thursday its financial results for the year ended Dec. 31, 2023. The San Diego-based company reported a gross margin of 44.3% for fiscal year 2023, representing an improvement from 34.2% for 2022. For the fourth quarter gross margin was 45.8%, representing a sequential improvement from 45.1% in the third quarter. "Our 2023 progress demonstrates our continuous commitment to innovation and cost-efficient execution as we move closer to profitability and positive cash flow," Joseph Dowling, CEO of CV Sciences, said. "As the CBD category consolidates, we have increased our market share in key sales channels, including the natural product retail channel. We will continue to focus our resources on new product development, as evidenced by our pet line expansion with our recent launch of pet chews for hip and joint health and calming care."

CVSI